We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Anti-Inflammatory Drug Spawns Potent Anticancer Drug

By Biotechdaily staff writers
Posted on 19 Jul 2004
Researchers have transformed an anti-inflammatory agent with mild antitumor properties into a potent anticancer drug that triggers apoptosis in treated cancer cells.

Investigators at Ohio State University (Columbus, USA) employed structure-activity analysis together with molecular modeling to generate derivatives of the cyclo-oxygenase 2 (COX-2) inhibitor celecoxib that were effective in inhibiting 3-phosphoinositide-dependent kinase-1 (PDK-1 kinase) activity. Two compounds were generated, OSU-03012 and OSU-03013, that were each 10 times more potent than celecoxib in inducing cancer cell death. These findings were reported in the June 15, 2004, issue of Cancer Research.

"This new agent works by inhibiting a fundamental signaling point in cancer cells, making it potentially effective in a wide range of cancer types,” said senior author Dr. Ching-Shih Chen, professor of pharmacy at Ohio State University. "We also have evidence that it may sensitize leukemia, and breast and lung cancers to conventional chemotherapy.”



Related Links:
Ohio State University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
HPV Test
Allplex HPV28 Detection

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
19 Jul 2004  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
19 Jul 2004  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
19 Jul 2004  |   BioResearch